Trevena (TRVN - Free Report) closed at $1.70 in the latest trading session, marking a +1.19% move from the prior day. This change outpaced the S&P 500's 1.9% loss on the day. At the same time, the Dow lost 1.77%, and the tech-heavy Nasdaq lost 2.5%.
Coming into today, shares of the biopharmaceutical company had gained 20.86% in the past month. In that same time, the Medical sector gained 2.84%, while the S&P 500 gained 3.04%.
Investors will be hoping for strength from TRVN as it approaches its next earnings release. The company is expected to report EPS of -$0.09, up 35.71% from the prior-year quarter.
Any recent changes to analyst estimates for TRVN should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 31.48% higher. TRVN is currently sporting a Zacks Rank of #1 (Strong Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 89, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.